Lilly Arthritis Drug Approved for Alopecia

    June 2022 in “ C&EN global enterprise ”
    Gina Vitale
    From the encyclopedia
    Baricitinib →

    JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

    Alopecia Areata →

    autoimmune disorder causing patchy hair loss

    Image
    Studysummary This source notes that Olumiant (baricitinib), a rheumatoid arthritis drug by Eli Lilly and Company, has been approved as the first systemic treatment for severe alopecia areata. Our plain-language summary of this paper — not a Tressless recommendation.
    Eli Lilly's rheumatoid arthritis drug, Olumiant (baricitinib), has been approved as the first systemic treatment for severe alopecia areata, an autoimmune condition causing hair loss. Olumiant is a daily pill and had also received emergency use authorization from the FDA in May for treating certain hospitalized COVID-19 patients.
    Discuss this study in the Community →